#	Pagina
attuale pagina	/open-h2020/projects/224444/index.html

Opendata, web and dolomites

TK-NEO SIGNED

Personalized Cancer Immunotherapy through DNA-EP vaccines

Total Cost €

EC-Contrib. €

Partnership

Views

TK-NEO project word cloud

Explore the words cloud of the TK-NEO project. It provides you a very rough idea of what is the project "TK-NEO" about.

tumor tumours tk sme 5m co validation exclusive week synthesis sequencing license mou gmp melanoma clinical pharma safety combining ip market confirm release stage authorization zero vaccine dna pricing final heterogeneous therapeutic financing right cancer respect patient instrument boosting immune neoantigen carry locally treatment metastatic protecting additional completion human alternative form validate manufacturing electroporation constituted ncvs feasibility neo days relapse applicability first immunity patented precision solid surgery trials humanized investment efficacy company ncv proven vaccination solution mice client patients chemotherapeutic takis perfect medicine reduce disease ep vc total maintenance fold lung tumors rna tumour underwent tests customized licensing anti sequence strategy

Project "TK-NEO" data sheet

The following table provides information about the project.

Coordinator	TAKIS SRL Organization address address: VIA DI CASTEL ROMANO 100 city: ROMA postcode: 128 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-08-01 to 2020-01-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	TAKIS SRL TAKIS SRL Organization address address: VIA DI CASTEL ROMANO 100 city: ROMA postcode: 128 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	coordinator	50˙000.00

Map

Project objective

TK-NEO is a DNA-based Neoantigen Cancer Vaccine (NCV), for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours. NCVs are a new form of precision medicine and are a perfect clinical approach for highly heterogeneous tumors in patients with metastatic disease. Takis has developed and patented a unique method for production of patient-specific NCVs based on a 6-week process, from sequencing the specific tumour DNA, synthesis of the right DNA sequence for the specific tumour, delivery through a specific Electroporation (EP) technology used under exclusive license. The solution was proven at pre-clinical stage to reduce to zero a human lung cancer in humanized mice in 60 days and to increase the efficacy several fold with respect to alternative RNA and DNA based NCVs in protecting relapse and boosting immune responses as required for the maintenance of long-term anti-tumor immunity. The strategy to reach the market for TK-NEO is to license the IP of TK-NEO to a large pharma company, after completion of clinical validation trials to demonstrate the applicability and safety of the approach: phase I clinical trials in melanoma are targeted during SME Instrument project, while implementation of a GMP manufacturing to carry out phase II clinical trials and the implementation of the trials will require additional 5M investment. The Total Available Market is constituted by melanoma patients who underwent surgery and first chemotherapeutic treatment, who are estimated in the order of 30.000 patients per year combining EU and US. The objectives of the feasibility study are: 1) to validate the feasibility and the authorization process for the release tests, 2) to confirm investment, cost and pricing for TK-NEO, 3) to define a MoU with VC or with the final client (pharma) for the co-financing of the clinical development of customized TK-NEO and for future licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TK-NEO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TK-NEO" are provided by the European Opendata Portal: CORDIS opendata.